Bank of America Corp DE Sells 137,220 Shares of Annexon, Inc. (NASDAQ:ANNX)

Bank of America Corp DE reduced its stake in shares of Annexon, Inc. (NASDAQ:ANNX) by 82.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 29,940 shares of the company’s stock after selling 137,220 shares during the period. Bank of America Corp DE’s holdings in Annexon were worth $154,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. E Fund Management Co. Ltd. raised its position in Annexon by 36.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after purchasing an additional 4,086 shares during the period. Comerica Bank raised its position in Annexon by 22.7% in the 4th quarter. Comerica Bank now owns 23,183 shares of the company’s stock worth $119,000 after purchasing an additional 4,283 shares during the period. Wellington Management Group LLP increased its position in shares of Annexon by 1.8% in the fourth quarter. Wellington Management Group LLP now owns 268,166 shares of the company’s stock valued at $1,376,000 after acquiring an additional 4,806 shares during the period. Rhumbline Advisers increased its position in shares of Annexon by 4.3% in the fourth quarter. Rhumbline Advisers now owns 141,852 shares of the company’s stock valued at $728,000 after acquiring an additional 5,854 shares during the period. Finally, Bank of New York Mellon Corp increased its position in shares of Annexon by 2.8% in the fourth quarter. Bank of New York Mellon Corp now owns 230,546 shares of the company’s stock valued at $1,183,000 after acquiring an additional 6,226 shares during the period.

Wall Street Analyst Weigh In

ANNX has been the topic of a number of analyst reports. HC Wainwright decreased their price objective on shares of Annexon from $20.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Needham & Company LLC reduced their price target on shares of Annexon from $16.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th.

Annexon Stock Performance

Shares of ANNX opened at $2.44 on Tuesday. The stock has a market cap of $267.70 million, a PE ratio of -2.32 and a beta of 1.26. Annexon, Inc. has a fifty-two week low of $1.29 and a fifty-two week high of $7.85. The firm’s 50-day simple moving average is $1.95 and its two-hundred day simple moving average is $3.06.

Annexon (NASDAQ:ANNX) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.07). Equities research analysts predict that Annexon, Inc. will post -0.96 EPS for the current year.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.